Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Multiple Myeloma Clinical Trial

Official title:

An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01023880
• Other study ID #: C18770/2043
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: December 1, 2009
• Last updated: February 9, 2016
• Start date: January 2010
• Est. completion date: January 2013

Study information

• Verified date: February 2016
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 62
• Est. completion date: January 2013
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

The patient has:

• relapsed multiple myeloma that has progressed following therapies that included bortezomib and an IMiD (thalidomide or lenalidomide) either alone or in any combination.

• multiple myeloma, which is refractory to the most recent therapy (bortezomib or IMiD, or any other chemotherapy), or the patient did not tolerate and discontinued the most recent therapy for multiple myeloma but has recovered from its toxic effects.

• measurable disease defined as 1 of the following:

• serum M-protein =0.5 g/dL

• urine M-protein =200 mg/24 hours

• a life expectancy of more than 3 months.

• an ECOG performance status of 0, 1, or 2.

• adequate hepatic organ function.

• an absolute neutrophil count (ANC), hemoglobin level, and platelet count within protocol-specific ranges.

• been independent of granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) support for more than 1 week.

• been independent of platelet transfusion for more than 1 week.

• received, or may have received, an allogeneic and/or autologous transplant.

• a creatinine clearance of 30 mL/minute or more as measured or as calculated based on the Cockcroft-Gault method.

• if the patient is a female of childbearing potential (not surgically sterile or 1 year postmenopausal): must use a medically accepted method of contraception (including abstinence) and must agree to continue use of this method for the duration of the study and for 3 months after participation in the study.

• if the patient is a male: is surgically sterile, or if sexually active, is currently using an effective barrier method of contraception, and agrees to continue use of this method for the duration of the study and for 3 months after the last administration of study drug.

Key Exclusion Criteria:

The patient:

• has nonmeasurable multiple myeloma.

• received glucocorticoid therapy (prednisone >10 mg/day orally or equivalent) within the last 2 weeks prior to the first dose of study drug.

• has POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy or monoclonal proliferative disorder, and skin changes).

• has plasma cell leukemia.

• received chemotherapy with approved anticancer therapeutics within 2 weeks, or within 5 drug half-lives (t1/2), or investigative anticancer therapeutics within 4 weeks, or within 5 drug half-lives (t1/2), before the first dose of study drug, whichever time is greater.

• received radiation therapy or immunotherapy in the 4 weeks prior to, or localized radiation therapy within 1 week prior to, the first dose of study drug.

• received prior treatment with CEP-18770.

• has used a medication known to be a potent inducer of CYP2E1, CYP2D6 or CYP3A4/5 within 4 weeks prior to the first dose of study drug.

• has used a medication known to be a potent inhibitor of CYP2E1, CYP2D6 or CYP3A4/5 within 2 weeks prior to the first dose of study drug.

• had major surgery within 3 weeks before the first dose of study drug.

• has congestive heart failure or had symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within the last 6 months.

• had an acute infection requiring systemic antibiotics, antiviral agents, or antifungal agents within 2 weeks before the first dose of study drug.

• has a known or suspected human immunodeficiency virus (HIV) infection on the basis of medical history.

• had a nonhematologic malignancy within the past 3 years except for the following:

adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or prostate cancer (Gleason grade <6 with prostate specific antigen (PSA) levels within the normal range).

• has myelodysplastic or myeloproliferative syndrome.

• has significant neuropathy.

• is a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study.

• has known central nervous system involvement.

• has any serious psychiatric or medical condition that could interfere with treatment or study procedures, place the patient at unacceptable risk, or hinder the interpretation of study data.

• has known hypersensitivity to mannitol or hydroxypropyl betadex.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• CEP-18770
CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.

Locations

Country	Name	City	State
United States	Northwestern University Medical School	Chicago	Illinois
United States	Henry Ford Health System Protocol Review Committee	Detroit	Michigan
United States	Duke University Medical Center	Durham	North Carolina
United States	John Theurer Cancer Center	Hackensack	New Jersey
United States	Sparrow Regional Cancer Center	Lansing	Michigan
United States	University of Arkansas for Medical Sciences	Little Rock	Arkansas
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Stanford Heme Group	Palo Alto	California
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of California, San Francisco	San Francisco	California
United States	Mayo Clinic- Scottsdale	Scottsdale	Arizona
United States	Washington University School of Medicine	St. Louis	Missouri
United States	Washington Cancer Institute	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)		Every 4 weeks, until completion of treatment	No
Secondary	Elapsed time from the ORR date to the date of disease progression (DOR)		at disease progression	No
Secondary	Elapsed time from the date of first dose of CEP-18770 to the date of first response (TTR) to treatment with CEP-18770		at date of first response (TTR) to treatment	No
Secondary	Elapsed time from the date of first dose of CEP-18770 to the date of disease progression (TTP)		at date of disease progression (TTP)	No